Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Adjunct Testing to Inform the Diagnosis of Dysplastic Nevi
Description
In a discussion on the adjunct testing used for diagnosing dysplastic nevi, the speaker emphasizes the importance of correlating histopathological features with biological behavior and genetic alterations in melanoma. They detail various testing methods, particularly immunostains such as P-16 and Ki-67, which help distinguish between benign nevi and malignant melanomas by assessing cell proliferation and the integrity of crucial genetic loci. The talk highlights the utility of PRAME as a marker, illustrating its effectiveness in differentiating between melanoma and dysplastic nevi based on expression patterns. Furthermore, it explores advances in molecular techniques like next-generation sequencing and FISH, which can identify genetic variations that underpin melanoma progression. Using case studies, the speaker explains how the interpretation of these results can lead to more informed diagnoses and treatment strategies. They also differentiate between types of dysplastic nevi based on their genetic profiles, suggesting a model for understanding their development and potential for malignancy. The session concludes with an acknowledgment of the collaborative efforts of a renowned dermatopathology team and the speaker's gratitude for the platform to share this vital information.
View moreConclusions
- Histopathology remains the primary method for diagnosing dysplastic nevi and melanoma.
- Immunohistochemical markers like p16 and Ki-67 assist in differentiating nevi from melanoma.
- Loss of p16 expression is indicative of malignant potential in melanocytic lesions.
- Elevated Ki-67 levels are more common in melanoma than in benign nevi, with some exceptions.
- PRAME expression is predominantly found in melanoma and absent in most dysplastic nevi, aiding diagnostics.
- Next generation sequencing (NGS) provides insights into genetic alterations in melanoma compared to benign nevi.
- Genomic instability is a critical factor that distinguishes melanoma from benign nevi.
- The study identifies distinct genomic patterns between type 1 and type 2 dysplastic nevi, correlating with histological features.
- Melanomas typically present with multiple genetic mutations, whereas benign nevi show limited or no such alterations.
- Understanding the molecular and genetic basis of dysplastic nevi and melanoma enhances diagnostic accuracy and treatment strategies.
- Am J Surg Pathol 2018:42:1456-1465
- Boris C. Bastian ,** Adam B. Olshen,t Philip E. LeBoit ,* t and Daniel Pinkelt American Journal of Pathology, Vol. 163, No. 5, November 2003
- N Engl J Med 2015;373:1926-36.
- PNAS Nexus, 2024, 3, 1-8